A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Indiana University
Study ID
NCT05733832
Status
Recruiting
Apply to this trial

Conditions

  • Liver Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Transitional Liver Clinic (TLC) — OTHER
    Participants in this intervention receive additional attention from their Hepatology providers in terms of an additional call/telemedicine visit and more specific/additional attention from their Hepatology APP (advanced practice provider) based on individual patient needs

Study Details

Patients with complications of advanced liver disease often have difficulties after hospital discharge that result in early hospital readmission. Poor outcomes for these patients during this transitional time could be improved through the use of innovative transitional care models. This proposal aims to examine the effect of a transitional care model, The Transitional Liver Clinic (TLC), in reducing hospital re-admissions, improving quality of life, and improving patient experience.

Key Dates

Start date
Sep 1, 2023
Status verified
Oct 2025
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
1,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • No Intervention: Control group
    Patients in the usual care arm will receive standard follow-up care from their usual providers based on recommendations made by inpatient providers at the time of discharge from the hospital.
  • Active Comparator: Transitional Liver Clinic (TLC)
    Enrolled patients discharged during the experimental TLC intervention implementation period will receive a phone call from TLC staff within 2 business days of discharge followed by an in-person or video telehealth clinic visit with a hepatology APP within 14 days of discharge. TLC staff will provide additional care based on individual patient needs during the 30-day transitional period.

Primary Outcome Measure

30-day hospital readmissions for patients hospitalized with complications of advanced liver disease [ Time Frame: 30 days after discharge of initial hospitalization at which the participant was enrolled in the study. ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
University of ChicagoChicagoIllinois60637
Michael Charleton, MD
[email protected]
773-702-1234
Indiana University Division of Gastroenterolgy and HepatologyIndianapolisIndiana46202
Regina Weber, BS, RRT
[email protected]
317-278-3584
Eric Orman, MD
[email protected]
317-278-1630
Eric Orman, MD (PRINCIPAL_INVESTIGATOR)
University of MichiganAnn ArborMichigan48109
Elliott Tapper, MD
[email protected]
734- 936-9250
Albert Einstein Healthcare NetworkPhiladelphiaPennsylvania19141
Victor Navarro, MD
[email protected]
215-456-8242

Find similar trials in Chicago, IL

By research site
University of Chicago· Chicago, ILIndiana University Division of Gastroenterolgy and Hepatology· Indianapolis, INUniversity of Michigan· Ann Arbor, MIAlbert Einstein Healthcare Network· Philadelphia, PA

Related Studies